CADL logo

CADL
Candel Therapeutics Inc

8,867
Mkt Cap
$320.61M
Volume
419,446.00
52W High
$13.68
52W Low
$4.25
PE Ratio
-10.49
CADL Fundamentals
Price
$5.87
Prev Close
$5.84
Open
$5.80
50D MA
$5.58
Beta
1.25
Avg. Volume
735,250.60
EPS (Annual)
-$1.74
P/B
4.02
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Candel Therapeutics (NASDAQ:CADL) Stock Rating Lowered by Zacks Research
Zacks Research cut shares of Candel Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Monday...
MarketBeat·13d ago
News Placeholder
More News
News Placeholder
New Strong Sell Stocks for January 20th
DAR, CADL and DRTS have been added to the Zacks Rank #5 (Strong Sell) List on January 20, 2026.
Zacks·14d ago
News Placeholder
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Brokerages
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight ratings firms that are covering the stock, MarketBeat reports...
MarketBeat·1mo ago
News Placeholder
Candel Therapeutics, Inc. $CADL is Acorn Capital Advisors LLC's 5th Largest Position
Acorn Capital Advisors LLC boosted its position in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) by 19.9% in the second quarter, according to the company in its most recent Form 13F filing...
MarketBeat·2mo ago
News Placeholder
Brookline Capital Management Weighs in on CADL Q4 Earnings
Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Stock analysts at Brookline Capital Management issued their Q4 2025 earnings estimates for Candel Therapeutics in a report issued on Sunday...
MarketBeat·2mo ago
News Placeholder
Stephens Reaffirms Overweight Rating for Candel Therapeutics (NASDAQ:CADL)
Stephens reaffirmed an "overweight" rating and set a $15.00 price target on shares of Candel Therapeutics in a research note on Monday...
MarketBeat·2mo ago
News Placeholder
Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight analysts that are currently covering the company, MarketBeat...
MarketBeat·2mo ago
News Placeholder
Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar
Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits.
Stocktwits·2mo ago
News Placeholder
Citigroup Cuts Candel Therapeutics (NASDAQ:CADL) Price Target to $24.00
Citigroup reduced their price target on shares of Candel Therapeutics from $25.00 to $24.00 and set a "buy" rating on the stock in a research report on Friday...
MarketBeat·3mo ago
News Placeholder
Candel Therapeutics (NASDAQ:CADL) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen downgraded shares of Candel Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·3mo ago
<
1
2
...
>

Latest CADL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.